Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
An ADC is a targeted therapy that delivers a potent drug directly to cancer cells.
The company said the 100 mg/m2 dose achieved a 50.0% objective response rate (ORR), meaning a significant reduction in tumor size, including two complete responses (CR), where all signs of cancer disappeared.
The median duration of response (mDOR), the time patients continued to respond to treatment, was not reached.
According to Ira Winer, a study investigator, these results are encouraging for patients with limited treatment options.
Genmab plans further evaluation in a Phase 2 and a planned Phase 3 trial, aiming to address an unmet need in gynecologic cancers, as stated by Judith Klimovsky, Chief Development Officer.
More from this issuer
Related coverage
Genmab said Monday it is raising $6 billion in debt through a combination of notes and loans to help fund its pending acquisition of biotechnology company Merus.
Genmab said Monday it is raising $6 billion in debt through a combination of notes and loans to help fund its pending acquisition of biotechnology company Merus.
Genmab A/S on Tuesday said it has commenced a cash tender offer to acquire all outstanding shares of Merus N.V. for $97.00 per share, formally launching its approximately $8 billion acquisition of the biotechnology company.
Genmab A/S said Saturday that updated data from a mid-stage trial showed its experimental drug, rinatabart sesutecan, demonstrated sustained anti-tumor activity in patients with advanced endometrial cancer.